In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Deal Gives Lundbeck US Foothold

Executive Summary

Lundbeck's $270 million deal with Merck & Co. to develop and commercialize the Phase III gaboxadol for sleep disorders in the US finally gives the Danish CNS specialist a foothold in the US market. Gaboxadol provides Merck an entry into the burgeoning insomnia market and the deal-the company's largest-ever single-product pact-is indicative of the Big Pharma's growing flexibility and acceptance of external research.

You may also be interested in...



Lilly Doubles Down on Insomnia with Hypnion Acquisition

Eli Lilly added its second insomnia program with the acquisition of privately held Hypnion Inc. Hypnion's Phase II HY10275 compound is the industry's most advanced dual H1/5HT2a antagonist in clinical development. Hypnion management told START-UP that M&A was its preferred exit, given the resources necessary to develop HY10275 to its full potential.

Insomnia: Pharma Wakes Up to the Next Huge CNS Market

The insomnia market is entering a growth spurt enabled and fueled by more effective and safer drugs and their intense promotion: think depression in 1990, without the social stigma. The recent launch of three new products-Sepracor Inc.'s eszopiclone (Lunesta), Takeda Pharmaceutical Co. Ltd.'s ramelteon (Rozerem) and Sanofi-Aventis' controlled-release zolpidem (Ambien CR)-and the advertising blitz that has accompanied Lunesta and Ambien CR, has brought the plight of insomnia sufferers to the fore. And as it grows, market shares in insomnia can shift quickly.

Pierre Fabre: Time to Reap R&D Rewards In-House

Recent Big Pharma deals validate Pierre Fabre's productive research, and underline mid-sized pharmas' importance as a product source. But the French group hasn't yet fully capitalized on its R&D.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel